Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

Ganan-Gomez, I.; Yang, H.; Ma, F.; Montalban-Bravo, G.; Thongon, N.; Marchica, V.; Richard-Carpentier, G.; Chien, K.; Manyam, G.; Wang, F.; Alfonso, A.; Chen, S.; Class, C.; Kanagal-Shamanna, R.; Ingram, J. P.; Ogoti, Y.; Rose, A.; Loghavi, S.; Lockyer, P.; Cambo, B.; Muftuoglu, M.; Schneider, S.; Adema, V.; Mclellan, M.; Garza, J.; Marchesini, M.; Giuliani, N.; Pellegrini, M.; Wang, J.; Walker, J.; Li, Z.; Takahashi, K.; Leverson, J. D.; Bueso-Ramos, C.; Andreeff, M.; Clise-Dwyer, K.; Garcia-Manero, G.; Colla, S.

doi:10.1038/s41591-022-01827-x

In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4) / Ganan-Gomez, I.; Yang, H.; Ma, F.; Montalban-Bravo, G.; Thongon, N.; Marchica, V.; Richard-Carpentier, G.; Chien, K.; Manyam, G.; Wang, F.; Alfonso, A.; Chen, S.; Class, C.; Kanagal-Shamanna, R.; Ingram, J. P.; Ogoti, Y.; Rose, A.; Loghavi, S.; Lockyer, P.; Cambo, B.; Muftuoglu, M.; Schneider, S.; Adema, V.; Mclellan, M.; Garza, J.; Marchesini, M.; Giuliani, N.; Pellegrini, M.; Wang, J.; Walker, J.; Li, Z.; Takahashi, K.; Leverson, J. D.; Bueso-Ramos, C.; Andreeff, M.; Clise-Dwyer, K.; Garcia-Manero, G.; Colla, S.. - In: NATURE MEDICINE. - ISSN 1078-8956. - 28:5(2022), pp. 1097-1097. [10.1038/s41591-022-01827-x]